Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022
Research Letter

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy

Author affiliations: Azienda Socio Sanitaria Territoriale, Sette Laghi, Varese, Italy (F. Novazzi, A. Baj, A. Genoni, F. Maggi); University of Insubria, Varese (F. Novazzi, A. Baj, A. Genoni, F. Maggi); Pisa University Hospital, Pisa, Italy (D. Focosi).

Cite This Article

Abstract

We report 25 cases of infection with SARS-CoV-2 Omicron variant containing spike protein L452R mutation in northern Lombardy, Italy. Prevalence of this variant was >30% in this region, compared with <0.5% worldwide. Many laboratories are using previously developed L452R-specific PCRs to discriminate Omicron from Delta mutations, but these tests may be unreliable.

According to PANGOlin phylogeny, the SARS-CoV-2 Omicron variant of concern (VOC) consists of B.1.1.529 sublineages BA.1, in which there are 36 further sublineages; BA.2, sometimes called stealth Omicron or Omicron 2, with 3 further sublineages), and BA.3. As of April 2, 2022, among the ≈2 million Omicron sequences deposited in GISAID, spike mutation L452R (S:L452R) had been reported at <0.5% prevalence in BA.1 (425 cases), BA.1.1 (1,441), BA.1.17 (630), BA.1.15 (1,848), BA.1.1.15 (67), BA.1.15.1 (571), BA.1.14 (123), BA.1.1.1 (150), BA.1.1.2 (30), BA.1.16 (116), BA.1.1.14 (138), BA.1.1.13 (107), BA.1.1.16 (40), BA.1.1.11 (117), BA.1.13 (38), BA.1.1.12 (11), BA.1.9 (430), BA.1.12 (73), BA.1.9 (430), BA.1.12 (73), BA.1.1.10 (11), B.1.13.1 (5), BA.1.1.4 (1), BA.1.1.8 (24), BA.1.1.3 (6), BA.1.3 (3), BA.1.5 (1), BA.1.1.7 (8), BA.1.6 (4), BA.1.1.5 (1), BA.1.2 (3), BA.1.4 (1), BA.1.16.1 (1), BA.2 (125), and BA.2.3 (22).

The microbiology laboratory at Azienda Socio Sanitaria Territoriale (ASST), Sette Laghi (Territorial Social Health Authority of the Seven Lakes; Varese, Italy), which serves a wide area of the northern Lombardy region of Italy, has started a whole-genome next-generation sequencing (NGS) program for SARS-CoV-2­­–positive patients who seek care at emergency departments, as well as healthcare workers and patients in selected wards at 5 referral hospitals. During December 3, 2021–January 27, 2022, we identified 301 patients who tested positive by qualitative real-time reverse transcription PCR, then had blood samples undergo NGS; 220 samples were positive for Delta VOC and 81 for Omicron VOC. Among the Omicron cases, 25 were positive for spike mutation L452R (S: L452R) (Table). Of the sequences that we deposited in the GISAID database (https://www.gisaid.org), 17 belonged to PANGOlin sublineage BA.1, 3 to BA.1.1, 2 to BA.3, and 3 to undetermined sublineages. This proportion corresponded to a L452R prevalence of 31% (25 of 81 Omicron-positive participants in our study), compared with <0.5% worldwide. The wide heterogeneity in viral sequences excluded the likelihood of local transmission chains and supported the hypothesis of multiple introductions and convergent gene evolution.

The Omicron VOC leads to lower hospitalization and intensive care unit admission rates than some other VOCs, although it is resistant to most spike monoclonal antibodies (A. Peralta-Santos, unpub. data, https://doi.org/10.1101/2022.01.20.477163). To be effective, sotrovimab and small chemical antivirals have to be administered in the first days after onset of symptoms (D.K. Rai, unpub. data, https://www.biorxiv.org/content/10.1101/2022.01.17.476644v1), a timeframe not compatible with that needed to perform and receive results from spike or whole-genome NGS.

Attempts are underway to develop Omicron-specific PCRs, but in the interim, many laboratories are exploiting previously developed, commercially available, variant-specific PCRs to more promptly discriminate Omicron from Delta variants, an approach that relies on identifying the S: L452R mutation. Convergent evolution has led S: L452 mutations to occur in time across many different variants of interest (e.g., L452R in SARS-CoV-2 Iota and Epsilon and L452Q in Lambda), accounting for an overall 60% prevalence among SARS-CoV-2 isolates deposited in GISAID as of January 30, 2022. However, under the current simplified understanding of the variant landscape, it had been supposed that L452R mutations occurred in nearly all Delta samples across hundreds of AY sublineages, but not in Omicron samples. Our data clearly show that the approaches now being use currently are at risk of becoming unreliable for identifying variants because of gaps in knowledge.

Of note, L452R has been associated not only with resistance to some monoclonal antibodies (1) but also with T-cell immunity escape (N. Le Bert, unpub. data, https://doi.org/10.1101/2022.01.20.477163). The population of the northern Lombardy area has 80% coverage for 2-dose/single vaccine and 56% of residents have received an additional booster (2). Under such heavy selective pressure from vaccine-elicited immunity, it is not surprising that Omicron mutations leading to T-cell escape have a fitness advantage, and hence their prevalence should continue to increase.

Dr. Novazzi is a research scientist at University of Insubria, Varese, Italy. Her research interests include emerging viral infections.

Top

Acknowledgment

D.F. wrote the first draft; A.G. performed sequencing; A.B. and F.N. provided data curation; F.M. conceived the study and revised the manuscript.

Top

References

  1. Starr  TN, Greaney  AJ, Dingens  AS, Bloom  JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2:100255. DOIPubMedGoogle Scholar
  2. Regione Lombardia. Territorial vaccine coverage [in Italian] [cited on 2022 Jan 29] https://www.regione.lombardia.it/wps/portal/istituzionale/HP/vaccinazionicovid/dashboard-vaccini-territorio

Top

Table

Top

Cite This Article

DOI: 10.3201/eid2806.220210

Original Publication Date: April 13, 2022

Table of Contents – Volume 28, Number 6—June 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Andreina Baj, University of Insubria, Via Dunant 5, Varese 21100, Italy

Send To

10000 character(s) remaining.

Top

Page created: April 06, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external